British Society for Integrative Oncology’s Post

📢 PH updates from the ESC Congress 2024 in London! 🌟 This year's European Society of Cardiology Congress 2024 highlighted the continued focus on pulmonary hypertension (PH), featuring sessions like "Current Pharmacological Treatments for Pulmonary Hypertension," "Chronic Thromboembolic Pulmonary Hypertension: Is It Worth Learning About?" and "Shaping the Future Management of Pulmonary Hypertension." These discussions underscored the progress being made in the field and the ongoing commitment to improving patient care. There is growing excitement around new medications entering the market and numerous ongoing trials, and the emphasis on integrating patient perspectives into clinical trials and guidelines marks an important shift. The inclusion of Patient-Reported Outcome Measures (PROMs) is essential to ensuring that treatments align with the real-world needs and experiences of patients. Additionally, advocating for early patient involvement in the drug research process remains a key priority. Let’s continue to push for patient-centered research and make sure our voices are heard every step of the way. The recent developments showcased at WSPH 2024 and ESC 2024 represent a significant step forward, promising a brighter future for all PH patients worldwide! 💪❤️ Learn more about our initative: www.phaeurope.org #ESC2024 #PulmonaryHypertension #PatientAdvocacy #Cardiology #MedicalResearch #FutureOfMedicine #PROMs Hipertensión Pulmonar Argentina PH Belgium - Pulmonale Hypertensie vzw Hipertensión Pulmonar España ORG Pacientes Fundación Contra la Hipertensión Pulmonar Asociación Nacional de Hipertensión Pulmonar ANHP Stichting Pulmonale Hypertensie / PH Association the Netherlands PH Serbia AIPI Italian Pulmonary Hypertension Association Fundación Ayúdanos a Respirar Sociedad Latina de Hipertensión Pulmonar HAPCHI Asociacion Chilena de Hipertension Pulmonar Pulmonary Hypertension Association of South Africa

Register NOW to attend this webinar today! Diagnostic Challenges and Opportunities in Alzheimer’s Disease Management, hosted by the NAMCP Medical Directors Institute   Tuesday, Sept. 17 1-2 p.m. ET; Noon-1 p.m. CT Registration is available free of charge at: https://lnkd.in/eN8JH2NF Approximately 16 million Americans are living with mild cognitive impairment and dementia and warrant a diagnostic evaluation to determine the cause of their cognitive decline. Accurate and timely detection of Alzheimer’s disease (AD) pathology in affected patients continues to be a significant hurdle to delivering optimal care for patients with signs and symptoms of cognitive decline. There is an urgent unmet need for safe, lower cost, less resource-intensive, easily accessible, and broadly available tests that identify the presence or absence of brain amyloid plaques, a pathological hallmark of AD. Current care may be improved using high performing blood biomarkers to potentially shorten the diagnostic journey and facilitate the early treatment of Alzheimer’s disease. Speakers: Ian Kremer, JD, Executive Director, LEAD (Leaders Engaged on Alzheimer's Disease) Coalition Suzanne Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine in St. Louis Joel Braunstein, MD, MBA, CEO and Co-Founder, C2N Diagnostics, LLC Learning Objectives: 1. Understand the value of early diagnosis in the care management of patients with cognitive impairment 2. Recognize the usual clinical care pathway for the evaluation of patients with cognitive impairment and new expert recommendations and appropriate use criteria on care management 3. Analyze the differences between different biomarker tests for brain amyloid and their approaches for helping clinicians diagnose Alzheimer’s disease 4. Evaluate the opportunity for a high-accuracy blood biomarker test to streamline diagnosis and management strategies https://lnkd.in/eN8JH2NF #webinar #Alzheimers #Alzheimersdisease #precisionmedicine #bloodbiomarkers #diagnosis

https://lnkd.in/guW_HPBV Article title: Lactate Dehydrogenase is involved in but not the Target Antigen in Children with Kawasaki Disease Author(s): Lanqing Zhao; Chunna Zhao; Zhongdong Du; Hongwu Du Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Background: Kawasaki disease (KD) is an acute vasculitis often complicating coronary arterial lesions, and gradually becomes the leading cause of acquired heart disease instead of rheumatism. Previous studies often regards elevation of serum lactate dehydrogenase (LDH) level as an auxiliary diagnosis marker when judging myocardial diseases. Methods: We analyzed the serum LDH levels in newly confirmed KD patients, compared with febrile non-KD patients and healthy donors as controls. Then a subtype of LDH protein (LDHA) were over-expressed and purified for antigenicity analysis of potential anti-LDHA autoantibodies in IgA, IgM and IgG isotype by homemade ELISA, respectively. #LactateDehydrogenase #KawasakiDisease #ExpressionAndPurification #AntigenicityAnalysis #AutoimmuneTarget #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Elevate ↗️ your understanding regarding ventilation strategies 🌬️ in Cardiogenic Shock 🫀 Once again, a must-read article🤓 for a better understanding of ventilation issues in patients suffering cardiogenic shock ‼️

Clinicians at King's College Hospital NHS Foundation Trust are leading the way in exploring a first-of-its-kind treatment for aplastic anaemia (AA) using cell therapy through the TIARA trial. Initial phase 1 results from the trial are promising, offering new hope to people living with AA. 🔗 https://lnkd.in/e7RiKZen AA is a rare and life-threatening condition where the bone marrow fails to produce enough blood cells, causing severe fatigue, infections, and bleeding risks. Current treatments, such as immune-suppressive therapy or stem cell transplants, are often insufficient or unsuitable for many patients. The trial is made possible through our collaboration with The Aplastic Anaemia Trust. Managed by King's Health Partners Haematology, this initiative brings together the expertise of 3 NHS Foundation Trusts in London with the academic prowess of King's College London. The TIARA trial represents a critical step forward in advancing patient care, potentially providing a better chance of survival and an improved quality of life. Video courtesy of King's College London. #AplasticAnaemia #RareDisease #LifeScienceResearch

LUDC researcher Olle Melander is hosting the last session at the cardiometabolic precision medicine symposium in Herlev. The symposium is organised by Steno Diabetes Center Copenhagen, LUDC and Skånes universitetssjukhus (Skåne University Hospital). The session focuses on visions and plans for the development and implementation of cardiometabolic precision medicine in the Öresund region.   Olle Melander is the leader of a new centre for precision medicine in Skåne, established in collaboration between Region Skåne and Lund University. He sees great potential for precision medicine to improve the treatment of patients with cardiovascular diseases and diabetes.   ”There is a lot of strong research in the Öresund region that focuses on how to improve the prevention and treatment of diabetes and cardiovascular diseases. The new centre's aim is to translate such research into clinical practice so that it benefits the patients,” says Olle Melander, senior consultant at Skåne University Hospital and professor of internal medicine at Lund University.   Steno Diabetes Center Copenhagen has established a Clinic for Precision Medicine with a focus on cardiometabolic diseases. The aim with work at the clinic is both to strengthen the individualised treatment of patients as well as to support the translation and implementation of precision medicine research into clinical practice. Magnus T. Jensen, CEO and professor at Steno Diabetes Center Copenhagen, is excited about ongoing collaborations and future collaboration possibilities within the precision medicine area in the region.   "At Steno Diabetes Center, we set ambitious targets to make sure that our clinical research will benefit the patients. I hope that our new precision medicine clinic and collaborations with researchers and clinicians in the Öresund region will help us reach our goals. Knowledge exchange between different research environments is crucial for us to succeed," says Magnus T. Jensen.   #precisionmedicine #diabetesresearch #diabetes #cardiovascular #cardiovasculardisease #exodiab

Important publication: Projected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic In the face of significant positive developments in terms of disease modifying therapies for Alzheimer's dementia, Prof. Seán Kennelly (DTI Co-Lead) and Colleagues at Tallaght University Hospital evaluated whether patients at a Regional Specialist Memory Clinic (RSMC) would be eligible (using Appropriate Use Criteria (AUC)) for treatment with one such therapy. Their goal, to see how many undifferentiated clinical patients attending the RSMC or a subset of patients with positive biomarkers for AD could qualify for therapy according to these criteria. Additionally, they compared how clinical trial eligibility rates differ when applying clinical trial criteria across the two groups. This work is particularly important for two reasons. Firstly, timely identification of eligible patients is key to ensuring that these new treatments are delivered during the optimum therapeutic window and secondly, appropriate clinical service design will hinge on improved understanding of future demands for treatment. Access this important paper here: https://lnkd.in/gjFwbcK4

Exercise for the prevention and treatment of chemo-induced peripheral neuropathy It turns out that exercise helps with yet another condition: chemo-induced peripheral neuropathy (CIPN). We knew about exercise’s potential role in treating CIPN. Still, new evidence shows that it can help prevent it! It is important to remember that many other things tried before (vitamins, supplements, medications, etc.) have failed to do so. Painful peripheral neuropathy is the most common, frustrating, and disabling symptom I see in patients who have received neurotoxic chemotherapy. It profoundly affects the quality of life, sleep, social functions, and work. Current treatments only offer modest benefits. They are also costly (estimated cost of treatment per patient: 17,000 USD). 📚 This JAMA Internal Medicine study (STOP trial) by @Fiona Streckmann explores prevention through structured exercise, specifically sensorimotor training (SMT) and whole-body vibration. The findings are intriguing: twice-weekly SMT sessions significantly reduced CIPN incidence and the need for chemotherapy dose modifications. 🏋️♀️ The SMT protocol was specific but manageable: - Balance exercises on unstable surfaces - 4 exercises, 3 sets each - 15-30 minutes, twice weekly How does it work? The treatment: • Affects the level of BDNF  • Improves blood perfusion  • Increases the sensitivity of mechanoreceptors ⚠️ Important context to remember: the study population was younger than typical cancer patients, with limited enrollment and adherence challenges. Also, only enrolled patients who received first-line chemotherapy. 🤔 In my practice, physical therapy has been a reliable ally in treating established CIPN. But these findings invite us to reimagine its role - not just as a response to symptoms, but as a proactive measure against one of chemotherapy's most challenging complications. 🔑 Could SMT as a preventative measure become a new treatment paradigm? Breaking down barriers of access while developing strategies for older patients and conducting further research on how best to implement the treatment could transform how we prevent this debilitating side effect. What has been your experience with exercise interventions in supportive cancer care? Tag: @American Physical Therapy Association @American Society of Clinical Oncology @Supportive Care in Oncology Network @MASCC #SupportiveCare #CancerCare #CIPN #PhysicalTherapy #SupportiveOncology #PeripheralNeuropathy #CancerRehabilitation (See first comment for links to study and resources)

The landscape of cardiovascular treatment may be poised for a shift as a large-scale trial challenges the conventional wisdom surrounding beta blocker use after heart attacks.  With around 5,000 patients enrolled, specifically those with preserved ejection fraction post-heart attack (HFpEF), the findings, presented at the American College of Cardiology conference and published in the NEJM, suggest a reevaluation may be in order. Traditionally, beta blockers have been a cornerstone in post-heart attack care, aimed at reducing stress on the heart by slowing its rhythm. However, this trial's results paint a different picture. Long-term beta blocker treatment showed no significant reduction in the combined risk of death or new heart attack among patients with preserved ejection fraction, defined in this study as over 50%. While patients on beta blockers showed a slight decrease in the combined risk of adverse outcomes compared to those who weren't, this difference was not statistically significant. Moreover, there were no significant differences in individual outcomes studied, nor in safety events between the two groups. Despite these compelling findings, it's essential to acknowledge the study's limitations, including its predominantly Swedish enrollment and underrepresentation of women—a persistent issue in cardiovascular research. Moreover, the absence of a placebo arm for patients not on beta blockers raises questions about potential biases. While further research is undoubtedly warranted, these findings compel us to critically assess and evolve our treatment approaches in the ever-evolving landscape of cardiovascular care. #healthcare #cardiology

After very inspiring days at the European Society of Cardiology Congress 2024, it is a good time to share some reflections: #ESC2024 was an amazing opportunity to see and feel the power of science – the energy and excitement around scientific innovations to achieve better health outcomes for patients with debilitating cardiovascular diseases. It was exciting to learn about the latest development and how the future is already here in many disease areas, like in hypertension and hyperlipidemia with new emerging treatment options. It was staggering to experience major late breaking clinical trial presentations, but it was equally heart-warming to listen to younger scientists' presentations about interesting topics like optimal management of hyperkalaemia. Last, but not least, it was a pleasure to meet many colleagues and experts from different parts of the world. You always learn something new in these meetings. Something that really struck me is the challenges we are currently facing in the diagnosis and treatment of heart failure (HF). Did you know that: 1. The 5-year survival rate after hospitalization with HFrEF can be as low as 25%. 2. Heart failure is still the leading cause of hospitalizations in people over 65 years of age and has the highest 30-day readmission rate among all medical conditions. 3. Heart failure not only impacts patients and their loved ones, but also places an immense strain on healthcare systems around the world. The annual global burden of heart failure is $346 billion USD and is projected to increase by 127% by 2030. 4. However, there is hope. We can improve patient outcomes through earlier intervention and prompt initiation of guideline-directed medical therapy. Thanks to tireless scientific research, there is also a better understanding of the genetics and biology of heart failure, allowing for the development of more targeted approaches that focus on specific disease drivers or subgroups of patients with particular combinations of disease drivers. Learn more https://bit.ly/3X0pLCZ #Astrazeneca #ESC24 #Cardiology #Hyperkalaemia #Heartfailure #Innovation #Pharma